CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al

Arthritis Rheum. 2013 Apr;65(4):1130-1. doi: 10.1002/art.37871.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / pharmacology*
  • Antigens, CD19 / metabolism*
  • Antirheumatic Agents / pharmacology*
  • B-Lymphocytes / drug effects*
  • Humans
  • Leukocytes, Mononuclear / drug effects*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD19
  • Antirheumatic Agents